Australia's Dimerix gains as first patient completes four years on kidney disease drug
05/10/2026 05:26
BUZZ-Australia's Dimerix gains as first patient completes four years on kidney disease drug ** Shares of Australia's Dimerix DXB.AX rise as much as 8.6% at A$0.245, hitting their highest level since September 21
** Stock headed for its best session since September 28, if trend holds
** Biopharmaceutical co says first patient has successfully completed co's two-year Open Label Extension Study for its kidney disease drug DMX-200
** Adds, participants in the OLE study were initially part of the ACTION3 Phase 3 trial group
** Adds, 93% of ACTION3 participants have opted to continue receiving the drug as part of OLE
** Co says data from OLE study may support future regulatory and commercial activities for DMX-200
** Stock down 56.4% YTD
(Reporting by Shravya Marakini in Bengaluru)
Recent news on Dimerix
See all newsBrief: Dimerix Says Mark Diamond To Retire As Chair
Australia's Dimerix gains as first patient completes four years on kidney disease drug
Brief: Dimerix Says Waiver Permits Security Grant To Skiptan Entities Without Shareholder Approval
Australia's Dimerix rises on patent approval in Mexico
Brief: Dimerix Secures A$34 Million Non-Dilutive Funding Facility